Related by context. All words. (Click for frequent words.) 74 confirmatory Phase III 72 phase IIa clinical 71 phase IIb clinical 70 phase IIa 70 Phase #b/#a clinical 69 hypoxia activated prodrug 69 Phase IIb III 69 Phase 1b clinical 68 Phase 1a clinical 68 Phase Ib clinical 68 Cand5 68 Phase IIb clinical 68 Phase Ib study 68 Phase Ib 68 CRMD# 68 Phase 1b trial 67 Phase Ib IIa 67 multicenter Phase II 67 Phase III multicenter 67 double blinded placebo 67 Zenvia ™ 67 Phase IIa clinical 67 JAK inhibitor 67 Phase 2a trial 67 phase IIb 67 PFO migraine 67 dextromethorphan quinidine 67 MIST II 67 Phase Ib II 67 PDE4 inhibitor 66 Initiates Phase II 66 FOLOTYN ® 66 Phase #b/#a 66 Phase III placebo controlled 66 phase Ib 66 Xcellerated T Cells 66 CURE AF 66 PRT# 66 phase Ib clinical 66 dose escalation Phase 66 trastuzumab DM1 T DM1 66 huC# DM4 66 Phase IIIb 66 pharmacokinetic PK study 66 fosbretabulin 66 prospective randomized placebo 65 rALLy clinical trial 65 pivotal bioequivalence 65 OvaRex R 65 IIa trial 65 Initiated Phase 65 multicenter Phase 65 randomized controlled multicenter 65 NP2 Enkephalin 65 INCB# [001] 65 registrational 65 reslizumab 65 Phase 2b clinical 65 PrevOnco 65 PDX pralatrexate 65 TLK# 65 Phase IIIb clinical 65 cannabinor 65 vidofludimus 65 Personalized Immunotherapy 65 BrachySil TM 65 nitric oxide donating prostaglandin 65 randomized Phase IIb 65 multicenter randomized placebo controlled 65 Pivotal Trial 65 GLP toxicology studies 65 MEND CABG II 65 phase 2a 65 sNDA submission 65 randomized multicenter 65 IMA# 64 Phase 2a 64 PF # [002] 64 Matrix Phase 2b 64 Aurexis 64 liposomal formulation 64 RhuDex ® 64 MAGE A3 ASCI 64 mertansine 64 SPIRIT FIRST 64 novel oral anticoagulant 64 TELINTRA R 64 LymphoStat B TM 64 phase IIb III 64 Phase IIB 64 confirmatory Phase 3 64 Phase 2b study 64 MEND CABG 64 Phase IIb clinical trials 64 Phase IIb 64 Phase 2b clinical trials 64 PROVENGE ® 64 ONCONASE R 64 Phase #/#a 64 Phase 2a clinical 64 dose escalation clinical 64 volociximab 64 BRIM2 64 Completes Patient Enrollment 64 GRNVAC1 64 Phase Ib clinical trials 64 Phase IIb trials 64 Phase 1b clinical trials 64 placebo controlled clinical 64 oral ridaforolimus 64 double blinded randomized 64 PHX# 64 APEX PD 64 OvaRex ® MAb 64 Aflibercept 64 alvespimycin 64 blinded randomized placebo controlled 64 ongoing Phase 1b 64 GAMMAGARD 64 ADVANCE PD 64 TELINTRA 64 octreotide implant 64 docetaxel Taxotere R 64 placebo controlled Phase 64 Plicera 64 tezampanel 64 PEG SN# 63 prospective multicenter randomized 63 SUCCEED trial 63 Archexin 63 synthetic retinoid 63 Phase III clinical 63 PI3K/Akt pathway inhibitor 63 Initiates Clinical 63 Luveniq 63 oral picoplatin 63 EDEMA3 63 GALNS 63 Xanafide 63 Phase III Pivotal 63 DEEP AF 63 Initiates Enrollment 63 label multicenter 63 dimebon latrepirdine 63 vapreotide acetate 63 Tarceva TM 63 Pimavanserin 63 lorvotuzumab mertansine 63 deforolimus 63 ORBIT II 63 MERLIN TIMI 63 Initiate Phase 63 Phase 2b kidney transplant 63 GENASIS clinical 63 IL# PE#QQR 63 Phase III 63 ularitide 63 StemEx 63 Phase IIa trials 63 prospective randomized multicenter 63 Lixivaptan 63 novel histone deacetylase 63 randomized controlled Phase 63 tramiprosate Alzhemed TM 63 Daclizumab 63 BRAF inhibitor 63 Dalbavancin 63 LymphoStat B belimumab 63 Fx #A 63 Phase IIa trial 63 IIa clinical 63 multicenter randomized double 63 phase IIIb 63 oral prodrug 63 KNS # 63 Phase 2b randomized 63 TM Drug Eluting 63 TransVax tm 63 Achieves Primary Endpoint 63 ZYBRESTAT fosbretabulin 63 vinorelbine tartrate 63 Phase 1b 63 sapacitabine CYC# 63 vivo glucose 63 hyaluronidase enzyme 63 Locteron ® 63 ILLUMINATE 63 CHAMPION PCI 63 Panzem R 63 evaluating tivozanib 63 Zenvia Phase III 63 Zenvia TM 63 inhaled AAT 62 ROCKET AF 62 catheter occlusion CO 62 TELCYTA 62 generation purine nucleoside 62 Phase III Psoriasis 62 initiate Phase 1b 62 bardoxolone 62 XL# XL# XL# 62 L BLP# 62 CA9 SCAN 62 bevasiranib 62 GED aPC 62 ORE# 62 MIVI III 62 investigational protease inhibitor 62 YONDELIS 62 lucinactant 62 investigational humanized monoclonal antibody 62 TOLAMBA 62 M Vax 62 SEPET TM 62 telomerase therapeutic 62 Medidur TM FA 62 CIP ISOTRETINOIN 62 LEP ETU 62 urocortin 2 62 Bicifadine 62 TMC# C# 62 ALVESCO ® 62 Fodosine 62 Anturol TM 62 multicenter Phase III 62 Novolimus 62 HGS ETR2 62 Phase 2b trial 62 Initiates Phase III 62 BRIM3 62 thorough QT 62 OncoVEX 62 Phase III psoriasis 62 Phase 2a clinical trials 62 Rescula 62 Phase II 62 Tyrima 62 LEVADEX ™ 62 placebo controlled Phase III 62 CCR5 mAb 62 Capesaris 62 pivotal Phase III 62 tezampanel NGX# 62 Resten NG 62 AeroLEF TM 62 Lucanix R 62 lintuzumab 62 RH1 62 topically applied SEPA 62 BLA filing 62 Phase III randomized placebo 62 evaluating Actimmune 62 Phase #b/#a trial 62 Androxal TM 62 acyclovir Lauriad R 62 PROTEGE 62 Phase III pivotal 62 initiated Phase Ib 62 signal detection CTSD 62 UPLYSO 62 SinuNase TM 62 EchoCRT 62 Surfaxin LS 62 Initiate Phase II 62 registrational trial 62 valopicitabine NM# 62 R#/MEM # 62 CINTREDEKIN BESUDOTOX 62 Pivotal Phase III 62 oral taxane 62 EXPLORE Xa 62 intranasal formulation 62 induced macular edema 62 arsenic trioxide injection 62 beta 1a 62 successfully commercialize Iluvien 62 Microplasmin 62 riociguat 62 PrevOnco ™ 62 neratinib 62 CCX# 62 INSPIRE Trial Phase III 62 PSN# [002] 62 torezolid phosphate 62 cathepsin K inhibitor 62 SPL# Gel vaginal microbicide 62 ALN HTT 62 Sym# 62 including eniluracil ADH 62 HCD# [002] 62 registrational clinical 62 STEDESA 62 Dacogen injection 62 oxymorphone ER 62 SNT MC# 62 Safinamide 62 confirmatory clinical 62 tanespimycin 62 evaluating Prochymal 62 AzaSite Plus 62 ToGA 62 initiate Phase IIa 62 PRIMO CABG 62 Panzem R NCD 62 ocular formulation 62 Vascular Wrap TM 62 cMET 62 MEK inhibitor RDEA# 62 candidate AQ4N 62 CB2 selective receptor agonist 62 huN# DM1 62 XIENCE TM 62 randomized Phase III 62 subcutaneous formulation 62 phase IIb study 62 XL# anticancer compounds 62 pseudobulbar affect PBA 62 phase IIb trial 62 interferon gamma 1b 62 Commences Phase 61 midstage clinical 61 orally inhaled migraine 61 FOLFOX6 chemotherapy regimen 61 Cintredekin Besudotox 61 EDEMA3 trial 61 Presents Preclinical 61 acetonide FA 61 Spiegelmer ® 61 dirucotide 61 GATTEX ® 61 Talabostat 61 GSK# [001] 61 ancrod 61 Iluvien ® 61 AAG geldanamycin analog 61 dose escalation trial 61 ABSORB trial 61 ruxolitinib 61 RELOVAIR ™ 61 Aryplase 61 SAR# [004] 61 unique alkylating agent 61 initiate Phase 2b 61 PHASE III 61 Entereg R 61 VITAL Trial 61 Traficet EN 61 GRN# 61 Aganocide 61 Vilazodone 61 Phase 2b Clinical Trial 61 ospemifene 61 RhuDex 61 nucleoside analog 61 multicentre randomized 61 RenalGuard System TM 61 MAP# 61 selective androgen receptor modulator 61 LCP AtorFen 61 Hsp# Inhibitor 61 IV APAP 61 Phase 1a 61 IIa trials 61 evaluating satraplatin 61 product platforms AZX# 61 initiated Phase 1b 61 telomerase inhibitor drug 61 multicenter prospective 61 Iloperidone 61 Glybera R 61 DPX Survivac 61 ICA # 61 ALVESCO R 61 lead Aganocide compound 61 Multiple Ascending Dose 61 Phase Ia 61 ENDEAVOR IV 61 delivery polymer matrix 61 Crofelemer budesonide foam 61 ENMD # 61 TAXUS Element Paclitaxel Eluting 61 Receives Orphan Drug Designation 61 clevidipine 61 brivaracetam 61 Liprostin 61 controlled multicenter 61 HepeX B TM 61 catheter occlusion 61 ATL# [001] 61 placebo controlled multicenter 61 GW# [003] 61 Lovaxin C 61 midstage trials 61 BAY #-# 61 peripherally acting 61 PLK1 SNALP 61 adipiplon 61 CEQ# 61 PANVAC VF 61 EGS# 61 Phase IIb Trial 61 SUTENT ® 61 RSD# 61 Phase IIa 61 randomized Phase 2b 61 INS# [001] 61 Zerenex 61 PD LID 61 Files Investigational 61 palifosfamide Zymafos TM 61 Pivotal Phase 61 preclinical efficacy 61 recombinant PSMA vaccine 61 DermaVir Patch 61 MoxDuo ® 61 Vidaza azacitidine 61 metaglidasen 61 QLT# 61 teriflunomide 61 Cloretazine ® 61 ORMD 61 CCR9 antagonist 61 Initiate Clinical Trial 61 Gentamicin Surgical Implant 61 Oral NKTR 61 ARRY # 61 REG1 61 elotuzumab 61 Neuvenge 61 AZILECT R 61 Viprinex TM 61 oral treprostinil 61 tolevamer 61 Synavive 61 Zelrix 61 RTP #i 61 relapsing multiple sclerosis 61 compound INCB# 61 assessing T DM1 61 XL# XL# 61 OMNARIS Nasal Spray 61 SinuNase ™ 61 Zemplar Capsules 61 velafermin 61 Azedra 61 ATPace TM 61 retinal vein occlusion induced 61 aldehyde dehydrogenase ALDH2 deficiency 61 PRECISE trial 61 Phase IIb randomized 61 receptor tyrosine kinase inhibitor 61 inhaled formulation 61 PSMA ADC 61 humanised monoclonal antibody 61 adecatumumab MT# 61 Hyphanox 61 Solazed TM 61 albiglutide 61 Bayer HealthCare Onyx Pharmaceuticals 61 AQ4N 61 highly selective inhibitor 61 BioNumerik 61 peginesatide 61 CUSTOM III 61 MelaFind R 61 liver resection surgeries 61 Tasimelteon 61 trastuzumab emtansine T DM1 61 Onalta ™ 61 Exherin 61 desvenlafaxine succinate 61 pharmacokinetics PK 61 GVAX ® 61 BR.# 61 DEB# 61 Hedgehog antagonist 61 novel therapeutic antibodies 61 Prospective Randomized 61 ATL# [002] 61 Angiocept 61 candidate deforolimus 61 Phase IIb trial 61 Tarvacin TM 61 Phase #/#a clinical 61 acute peripheral arterial 61 small molecule glucokinase 61 OMAPRO ™ 61 Maximum Tolerated Dose MTD 61 intravenous AAT 61 IMPACT DCM 61 Saforis 60 Silodosin 60 Urocidin TM 60 Allovectin 7 60 triphendiol 60 Deferiprone 60 Submits IND 60 Exherin TM 60 Vernakalant 60 BiTE R 60 delivers fluocinolone acetonide FA 60 LEVADEX TM 60 markets HP Acthar 60 Troxatyl 60 Zoraxel 60 CRLX# 60 Neurodex 60 Trofex 60 virus HCV protease inhibitor 60 entinostat 60 plasma kallikrein inhibitor 60 Glufosfamide 60 MNTX 60 HGS# 60 Shigamabs ® 60 docetaxel Taxotere ® 60 Soliris eculizumab 60 Phase IIa proof 60 MKC# MT 60 Serdaxin ® 60 Meets Primary Endpoint 60 ganaxolone 60 RGB # 60 TMC# [002] 60 Simulect 60 XL# SAR# 60 AERx iDMS 60 multicenter clinical 60 RezularTM 60 LE DT 60 oncolytic virus therapies 60 CCX# B 60 BEMA TM Fentanyl 60 Anavex #-# 60 Diamyd R 60 Phase III randomized controlled 60 multicenter multinational 60 fully bioabsorbable 60 Plecanatide 60 Litx 60 ARIKACE ™ 60 orally dosed 60 lumiliximab 60 fidaxomicin Phase 3 60 Targretin capsules 60 Targretin 60 pharmacodynamic PD 60 Hedgehog Pathway Inhibitor 60 controlled multicenter Phase 60 pharmacokinetic PK 60 HGS ETR1 mapatumumab 60 Anturol 60 TKB# 60 Motesanib 60 samalizumab 60 EOquin TM 60 BRILINTA 60 NasdaqGM SPPI 60 Dual Opioid 60 PDE# inhibitors 60 SAR# [002] 60 somatostatin analogue 60 multicenter placebo controlled 60 Factor VIIa 60 Fludara ® 60 Telatinib 60 LUVENIQ 60 Ridaforolimus 60 prostone 60 Successfully Completes Phase 60 MAA submission 60 Diamyd ® 60 MKC# MKC# PP 60 II Clinical Trial 60 evaluating bafetinib 60 PRECISE 60 Guanilib 60 phase III isavuconazole 60 NV1FGF 60 SPARLON 60 visilizumab 60 Phase III Clinical Trial 60 Sapacitabine 60 ZYBRESTAT TM 60 DU #b 60 HCV NS5B polymerase 60 Genz # 60 Quinamed 60 JAK2 Inhibitor 60 Ophena 60 Pivotal Study 60 methylnaltrexone 60 Temsirolimus 60 Phenoptin 60 Acetavance TM intravenous acetaminophen 60 baminercept 60 LE SN# 60 SILENOR 60 Trastuzumab DM1 60 Ketotransdel 60 PROTECT AF 60 Veronate 60 preclinical pharmacokinetic 60 ThermoDox ® clinical 60 5 HT2A inverse 60 viral kinetic 60 Phase lll 60 omega interferon 60 Aplidin 60 HuMax TAC 60 Pafuramidine 60 unblind 60 lexidronam injection 60 next generation URAT1 60 Amoxicillin PULSYS Phase III 60 TRANSDUR ® 60 Voraxaze 60 Presents Preclinical Data 60 RhuDex TM 60 nalbuphine ER 60 AIMM trial 60 PolyActive ® 60 Deforolimus 60 balsalazide tablet 60 unblinding 60 CLIRS trial 60 Kahalalide F 60 JZP 60 IND submission 60 confirmatory pivotal 60 Initiates Phase 2b 60 Romidepsin 60 PRECISE Trial 60 miconazole Lauriad R 60 dirucotide MBP# 60 MoxDuo 60 Vitaxin 60 Cleviprex TM clevidipine 60 cetuximab Erbitux R 60 DCVax R 60 ANCHOR trial 60 Phase III VISTA 60 Perforomist ™ Inhalation Solution 60 EXPAREL TM 60 Lymphoseek ® 60 IMPACT IMmunotherapy 60 Xcytrin R 60 romidepsin 60 Ozarelix 60 forodesine hydrochloride 60 humanized monoclonal 60 forodesine 60 DASISION 60 Vicriviroc 60 KRN# 60 MT#/MEDI-# 60 mg/m2 cohort 60 Randomized Phase 60 Clolar ® 60 Panzem NCD 60 Lispro 60 Neo Bladder Augment 60 vascular disrupting agent 60 dacetuzumab 60 AIR CF1 60 Receives Approvable Letter 60 Combidex 60 OMS# 60 Pegloticase 60 PEGylated interferon beta 1a 60 Prosaptide 60 Apoptone 60 ZEVALIN ® 60 AKT inhibitor 60 tiapamil 60 CALGB # [002] 60 Phase IIb Clinical Trial 60 drug eluting coronary stent 60 Alocrest 60 SURFAXIN r 60 Triapine 60 Cethromycin 60 Ereska 60 multicenter randomized Phase 60 DURIN TM 60 oral antiviral 60 Randomized Double blind 60 WX UK1 60 3 registrational trial 60 pralatrexate injection folate analogue 60 PRIMO CABG2 60 antibody MAb 59 Corlux 59 EP #R 59 tubulin inhibitor 59 mGluR2 positive 59 personalized cellular immunotherapy 59 CardioFit 59 Eluting Coronary Stent System 59 Annamycin 59 PresbyLens ® 59 oral renin inhibitor 59 label multicenter Phase 59 PROPEL trial 59 lintuzumab SGN 59 Denufosol 59 investigational pan BCR 59 opioid induced bowel dysfunction 59 Ceragenin ™ 59 XIENCE V Everolimus Eluting 59 orally administered inhibitor 59 fostamatinib 59 CIP TRAMADOL ER 59 occlusion PAO 59 theranostic 59 CINQUIL 59 Nasdaq DVAX 59 personalized dendritic 59 NUVIGIL ® 59 NOX E# 59 REOLYSIN ® 59 class mGluR5 inhibitor 59 OncoGel 59 Octreolin 59 brand ciclesonide HFA 59 Ophthotech 59 LEUKINE 59 BiovaxID TM 59 Fibrillex TM 59 Vascugel ® 59 Prostate AdenoCarcinoma Treatment 59 targeted radiotherapeutic 59 ganetespib 59 Mycophenolate Mofetil 59 sitaxsentan 59 multicenter phase 59 Orapred ODT 59 OncoVex 59 Cloretazine R VNP#M 59 Omacetaxine 59 ASTEROID 59 severe hypercholesterolemia 59 Elagolix 59 BAL# [002] 59 Nipent R 59 HDAC Inhibitor 59 Glybera 59 ABL inhibitor 59 Pagoclone 59 leading oral taxane 59 personalized immunotherapy 59 Teysuno 59 EVIZON TM 59 orBec 59 Fibrin Pad 59 Iluvien TM 59 Neovasc Reducer 59 candidates Azedra TM 59 XL# XL# XL# XL# 59 preclinically 59 Begins Dosing 59 TBC# 59 Optiquel ™ 59 Allovectin 7 ® 59 trodusquemine 59 non nucleoside inhibitor 59 oral salmon calcitonin 59 IMPACT DCM clinical 59 Ostabolin C TM 59 Testosterone MDTS ® 59 histamine dihydrochloride 59 XmAb# 59 Curaxin CBLC# 59 Icatibant 59 ZoMaxx 59 GetGoal Phase III 59 MKC# 59 CLORETAZINE TM VNP#M 59 Intravail R 59 ALTROPANE R 59 Besivance 59 multicentre randomized double 59 Oral Insulin 59 Novel Oral 59 Spheramine 59 Phase 2a Study 59 Firazyr 59 HDL Selective Delipidation 59 subcutaneously administered 59 ™ pralatrexate injection 59 Blinatumomab 59 glucokinase activator 59 afamelanotide 59 Therapeutic Competitors Companies 59 polymerase inhibitor 59 Carfilzomib 59 BLOOM DM 59 comparing XIENCE V 59 ACCLAIM II 59 oral deforolimus 59 human IgG1 monoclonal 59 OvaRex 59 Tolvaptan 59 Mipomersen 59 Oxytrex TM 59 HuLuc# 59 ILUVIEN ® 59 allosteric modulator NAM 59 proteasome inhibitor 59 R lenalidomide 59 efficacy tolerability 59 Catena ® 59 TOCOSOL Camptothecin 59 bioequivalency 59 Clonicel 59 randomized blinded 59 BLA submission 59 Bezielle 59 Azedra TM 59 Nexavar sorafenib tablets 59 Phase IIa clinical trials 59 molecular imaging radiopharmaceutical 59 Completes Enrollment 59 PNP inhibitor 59 opioid naive 59 EVIZON TM squalamine lactate 59 Diabetic Macular Edema DME 59 BioSTAR R 59 CDP# 59 GV# [001] 59 SinuNase 59 USL# 59 evaluating CK # 59 DUROS 59 ascending dose 59 trastuzumab DM1 59 generation URAT1 inhibitor 59 MAXY alpha 59 Submits NDA 59 BrainGate TM 59 Aeroquin 59 Phase 2b 59 Altropane 59 axitinib 59 erlotinib Tarceva ® 59 Telik logo TELINTRA 59 SCH # 59 ADP receptor antagonist 59 NEUGENE antisense 59 PORxin TM 59 AVERROES 59 APTIMA HPV assay 59 CA4P 59 BioSTAR ® 59 Investigational Oral 59 denileukin diftitox 59 EndoTAG TM 59 Onconase 59 StaphVAX R 59 ABSORB clinical 59 pradefovir 59 Proellex TM 59 Genasense ® oblimersen 59 rxRNA 59 registrational studies 59 randomized #:#:# 59 randomized blinded placebo 59 PXD# 59 EndoTAG TM -1 59 anticancer compound 59 mitogen activated ERK kinase 59 Pyridorin 59 ocrelizumab 59 randomized discontinuation 59 European Sepsis Trial 59 Shows Statistically Significant 59 rilonacept 59 ZOLINZA 59 evaluating mipomersen 59 somatostatin analog 59 Methylnaltrexone 59 multicenter randomized 59 Teriflunomide 59 GRAVITAS trial 59 Shigamabs R 59 ALN TTR# 59 Alfimeprase 59 KIACTA ™ 59 Liposomal 59 Dyloject TM 59 small molecule chemotherapeutic 59 LibiGel ® 59 IPX# 59 NeoDisc 59 novel synthetic PEGylated 59 5 HT3 antagonist 59 QTinno TM 59 Valtropin 59 GOUT 59 TRISENOX ® 59 PEARL SC 59 Pirfenidone 59 ThermoDox R 59 Ocrelizumab 59 Dose Ranging Study 59 orally inhaled 59 Panzem 59 P#X# antagonist 59 ARIKACE 59 GEM OS2 59 budesonide foam 59 adenosine injection 59 IPL# 59 r hGH 59 Tracleer R 59 NeuroFlo 59 vascular disrupting agents 59 MVA MUC1 IL2 59 otelixizumab 59 mGluR5 negative 59 Unit Dose Budesonide 59 DDP# 59 Nanobody 59 bicifadine 59 Combination REOLYSIN R 59 TRANSFORMS 59 Inhalation Solution 59 Veronate R 59 regorafenib 59 multiple ascending dose 59 RSD# oral 59 Benlysta belimumab 59 mTOR inhibitor 59 NeuroSTAT ® 59 dyskinesia PD LID 59 CBLC# 59 Initiates Clinical Trial 59 Oracea TM 59 Tezampanel 59 Exelixis compounds 59 ASONEP 59 Survivin antagonist 59 Enhanze Technology 59 REG1 Anticoagulation System 59 TRANSDUR ™ 59 EOS NASDAQ MELA 59 rindopepimut 59 Ampakine 59 ELADUR TM 59 T Pred 59 Vascular Disrupting Agent 59 histone deacetylase HDAC inhibitor 59 immunotherapeutic vaccine 59 pertuzumab 59 methylnaltrexone bromide 59 AVN# Phase 59 Presents Positive 59 ALN PCS 59 Fentanyl TAIFUN R 59 Zorbtive TM 59 immunomodulatory therapy 59 memantine HCl 59 Allovectin 7 R 59 tasimelteon 59 TEMSO 59 senicapoc 59 Investigational Device Exemption 59 Inhalation Aerosol 59 candidates Dyloject TM 59 Laquinimod 59 VNP#M 59 ARISE Phase III 59 aplindore 59 systemic RNAi therapeutic 59 dalbavancin 59 hypoxia selective 59 LUMINATE 59 Zemiva ™ 59 NASDAQ ARRY 59 Prestara 59 ® bortezomib 59 Hepatocellular Carcinoma HCC 59 LibiGel Phase III 58 aclidinium bromide 58 Perceiva 58 neuronal nicotinic receptor NNR 58 Cloretazine 58 THALOMID 58 subcutaneous PRO 58 TAXUS Element Stent System 58 Stimuvax R 58 RECOTHROM R 58 OMNARIS HFA 58 celgosivir 58 HQK 58 long acting muscarinic 58 RE MODEL 58 rusalatide acetate 58 Tesamorelin